JPMorgan Chase & Co. Has $676,000 Stake in Pharvaris N.V. $PHVS

JPMorgan Chase & Co. lifted its holdings in Pharvaris N.V. (NASDAQ:PHVS) by 710.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,085 shares of the company’s stock after buying an additional 23,743 shares during the period. JPMorgan Chase & Co. owned approximately 0.05% of Pharvaris worth $676,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tudor Investment Corp ET AL purchased a new position in shares of Pharvaris in the 3rd quarter worth approximately $1,943,000. Boothbay Fund Management LLC boosted its stake in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the last quarter. General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the last quarter. Patient Square Capital LP boosted its stake in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after buying an additional 101,098 shares during the last quarter. Finally, Baker BROS. Advisors LP purchased a new position in shares of Pharvaris in the 3rd quarter worth approximately $9,356,000.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $26.63 on Monday. The stock has a market capitalization of $1.74 billion, a PE ratio of -7.90 and a beta of -2.58. The firm’s 50 day moving average is $27.05 and its 200 day moving average is $25.53. Pharvaris N.V. has a 12 month low of $11.66 and a 12 month high of $29.85.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada cut their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday. Wolfe Research assumed coverage on Pharvaris in a research note on Thursday. They issued an “outperform” rating and a $42.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.73.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris’ growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

Insider Activity at Pharvaris

In related news, CEO Berndt Modig sold 23,333 shares of Pharvaris stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total value of $647,257.42. Following the sale, the chief executive officer owned 142,084 shares of the company’s stock, valued at approximately $3,941,410.16. The trade was a 14.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.